Výsledky vyhledávání - "Yoshihiko Sakata"

Akademický článek

Real-World Data Analysis of Pembrolizumab Monotherapy for NSCLC Using Japanese Postmarketing All-Case Surveillance Data

Autor: Hideki Terai, MD, Kenzo Soejima, MD, Asanao Shimokawa, PhD, Hidehito Horinouchi, MD, Junichi Shimizu, MD, Tetsunari Hase, MD, Ryota Kanemaru, MD, Kana Watanabe, MD, Kiichiro Ninomiya, MD, Naoko Aragane, MD, Noriko Yanagitani, MD, Yoshihiko Sakata, MD, Masahiro Seike, MD, Daichi Fujimoto, MD, Masashi Kasajima, MD, Akihito Kubo, MD, Sojiro Kusumoto, MD, Yoshitaka Oyamada, MD, Keiichi Fujiwara, MD, Masahide Mori, MD, Midori Hashimoto, MD, Masato Shingyoji, MD, Masahiro Kodani, MD, Jin Sakamoto, MD, Toshihiko Agatsuma, MD, Kosuke Kashiwabara, MD, Minehiko Inomata, MD, Motoko Tachihara, MD, Kazuhisa Tanaka, MD, Kenji Hayashihara, MD, Nobuyuki Koyama, MD, Kaoru Matsui, MD, Koichi Minato, MD, Daisuke Jingu, MD, Hiroyuki Sakashita, MD, Satoshi Hara, MD, Tomoyuki Naito, MD, Asuka Okada, MD, Masayuki Tanahashi, MD, Yuki Sato, MD, Koichiro Asano, MD, Takayuki Takeda, MD, Kensuke Nakazawa, MD, Toshiyuki Harada, MD, Kazuhiko Shibata, MD, Tatsuo Kato, MD, Etsuo Miyaoka, PhD, Ichiro Yoshino, MD, Akihiko Gemma, MD, Tetsuya Mitsudomi, MD

Publikováno v: JTO Clinical and Research Reports, Vol 3, Iss 11, Pp 100404- (2022)

Introduction: Pembrolizumab is a programmed death-ligand 1 inhibitor that was initially indicated for monotherapy in patients with advanced lung cancer. The Japanese Lung Cancer Society conducted an observational study on pembrolizumab using confirma

Externí odkaz: https://doaj.org/article/67a827674fcd4c4087dafceff77375be

Zobrazit plný text záznamu

Akademický článek

Efficacy of Immune Checkpoint Inhibitor With or Without Chemotherapy for Nonsquamous NSCLC With Malignant Pleural Effusion: A Retrospective Multicenter Cohort Study

Autor: Hayato Kawachi, MD, Motohiro Tamiya, MD, Yoshihiko Taniguchi, MD, Toshihide Yokoyama, MD, Shinya Yokoe, MD, Yuko Oya, MD, PhD, Mihoko Imaji, MD, Fukuko Okabe, MD, Masaki Kanazu, MD, Yoshihiko Sakata, MD, Shinya Uematsu, MD, Satoshi Tanaka, MD, Daisuke Arai, MD, PhD, Go Saito, MD, Hiroshi Kobe, MD, Eisaku Miyauchi, MD, PhD, Asuka Okada, MD, PhD, Satoshi Hara, MD, Toru Kumagai, MD, PhD

Publikováno v: JTO Clinical and Research Reports, Vol 3, Iss 7, Pp 100355- (2022)

Introduction: Malignant pleural effusion (MPE) is associated with poor treatment outcome in patients with NSCLC receiving immune checkpoint inhibitors (ICIs). ICIs and chemotherapy (ICI/Chemo) combination therapy is currently the standard therapy for

Externí odkaz: https://doaj.org/article/a1964b63c30847029c4b83600c97ce97

Zobrazit plný text záznamu

Akademický článek

Comparisons between tumor burden and other prognostic factors that influence survival of patients with non‐small cell lung cancer treated with immune checkpoint inhibitors

Autor: Yoshihiko Sakata, Kodai Kawamura, Kazuya Ichikado, Naoki Shingu, Yuko Yasuda, Yoshitomo Eguchi, Jumpei Hisanaga, Tatsuya Nitawaki, Miwa Iio, Yuko Sekido, Aiko Nakano, Takuro Sakagami

Publikováno v: Thoracic Cancer, Vol 10, Iss 12, Pp 2259-2266 (2019)

Abstract Background The use of baseline tumor burden (TB) as a prognostic factor for non‐small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICIs) and associations between TB and other prognostic biomarkers remain unc

Externí odkaz: https://doaj.org/article/e0b95cd5f5cc496c9d8c55c4423f8f46

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Case report: continued treatment with alectinib is possible for patients with lung adenocarcinoma with drug-induced interstitial lung disease

Autor: Tatsuya Nitawaki, Yoshihiko Sakata, Kodai Kawamura, Kazuya Ichikado

Publikováno v: BMC Pulmonary Medicine, Vol 17, Iss 1, Pp 1-4 (2017)

Abstract Background Alectinib, a second-generation anaplastic lymphoma kinase (ALK) inhibitor, is a key drug for ALK rearranged lung adenocarcinoma. Interstitial lung disease (ILD) is an important adverse effect of alectinib, which generally requires

Externí odkaz: https://doaj.org/article/191e4ad0b98b4f37a6378b2ea25167b0

Zobrazit plný text záznamu

Akademický článek

A Case of Orbital Metastasis as Disease Progression of Anaplastic Lymphoma Kinase-Positive Lung Cancer Treated with Crizotinib

Autor: Yoshihiko Sakata, Kodai Kawamura, Kazuya Ichikado, Masakazu Yoshioka

Publikováno v: Case Reports in Oncology, Vol 8, Iss 1, Pp 21-24 (2015)

Orbital metastasis of lung cancer is rare. It often causes visual disorder. To date, there are only a few case reports. Crizotinib is an anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor that leads to responses in most patients with ALK-posi

Externí odkaz: https://doaj.org/article/0ab9b5033e0c40f5bf0d827a98f6acea

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání